Project Grant R01HL187653
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $623K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Oklahoma Health Sciences Center $638,245 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hypothalamic melanocortin 4 receptor (MC4R) signaling pathways in sympathetic regulation of blood pressure, with particular focus on obesity-induced hypertension mechanisms. The research examines how MC4R signaling in hypothalamic neurons regulates sympathetic outflow and blood...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $143,080 on December 6, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the cardiotoxic effects of monoamine oxidase (MAO) metabolism of catecholamines in obesity. The award funds a dissertation project investigating how three reactive metabolites produced by MAO—hydrogen peroxide, ammonia, and catecholaldehydes—individually contribute to mitochondrial dysfunction and...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $743,341 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the role of insulin receptor substrate 2 (IRS2) in cardiac calcium homeostasis and arrhythmogenesis. The research addresses sudden cardiac death from ventricular arrhythmias following myocardial infarction, driven by chronic sympathetic overactivation that disrupts cardiomyocyte calcium homeostasis and triggers...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $599,466 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research examining the cellular and molecular mechanisms driving submucosal gland hypertrophy in chronic lung diseases including asthma, COPD, and cystic fibrosis. The funded research will identify fundamental pathways responsible for pathological gland enlargement by defining key cell-cell interactions and signaling...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $660,875 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on TGF-β signaling in the pathogenesis of lymphangioleiomyomatosis (LAM). The recipient will engineer novel multicellular three-dimensional organoid and lung-on-chip models to test the effects of TGF-β signaling on the growth of LAM nodules and to identify mechanisms that drive nodule growth and alveolar...
- The University of Iowa received a $612,186 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion scheduled for May 31, 2029. The research investigates the role of lysosomal dysfunction in heart failure with preserved ejection fraction (HFpEF), specifically examining how gamma interferon-inducible thiol reductase (GILT) dysfunction contributes to cardiac immuno-metabolic...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $1,288,998 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate junctophilin-2's role in cardiac fibroblast calcium signaling and injury-induced cardiac fibrosis. The project employs advanced molecular, physiological, and biochemical techniques along with innovative mouse models to elucidate the mechanisms through which junctophilin-2 influences cardiac fibroblasts and...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $631,543 on June 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop gene therapies targeting junctophilin-2 for heart failure treatment. The research focuses on restoring excitation-contraction coupling function and correcting maladaptive transcriptional reprogramming in heart failure with reduced ejection fraction. The project leverages adeno-associated virus (AAV) vectors to...
- The National Heart, Lung, and Blood Institute awarded Des Moines University a project grant of $536,335 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research to identify physiological and biochemical mechanisms by which sleep apnea contributes to hypertension and kidney dysfunction. The recipient will expose male, female, and ovariectomized female rats to chronic intermittent hypoxia and measure arterial pressure, renal blood flow,...
- The National Heart, Lung, and Blood Institute awarded the University of Missouri System $840,770 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the interplay of central and peripheral vascular effects of insulin in obesity. The research focuses on skeletal muscle blood flow impairment and glucose uptake dysregulation in individuals with obesity and insulin resistance. The project examines how central (brain) insulin sensitivity drives sympathetic...